OLDWICK, N.J., Nov. 8, 2018 /PRNewswire/ --
Q3 2018 and Recent Corporate Highlights:
Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2018, and provided a business update.
"Provention has continued to build momentum since completing our initial public offering in July. Our just-announced co-development agreement with Amgen and in-licensing of AMG-714 (PRV-015), is a clear indication that our strategic vision of intercepting and preventing immune-mediated disease is compelling and resonates with industry leaders and innovators," stated Ashleigh Palmer, CEO of Provention Bio. "In just eighteen months since our founding financing, we have been able to build a deep and diversified pipeline that now includes six programs targeting the interception and prevention of chronic autoimmune diseases including type 1 diabetes, Crohn's disease, ulcerative colitis, lupus, and celiac disease. In so doing, we have demonstrated a unique ability to customize strategically aligned relationships that leverage the strengths, expertise, resources, and even manufacturing capabilities of technology originators, licensors and partners, including Janssen Pharmaceuticals and, now, Amgen."
Mr. Palmer concluded, "Looking ahead, we expect the fourth quarter and 2019 to be a period of continued growth and momentum for Provention as we advance our clinical programs targeting upstream processes that could substantially improve the lives of patients and their families who must endure the suffering and bear the burden of immune-mediated disease."
Third Quarter 2018 and Recent Activities:
As of September 30, 2018, Provention had cash and cash equivalents of $64.3 million. In July 2018, the Company completed its initial public offering which generated approximately $59.3 million in net proceeds after deducting commissions and expenses.
Net loss for the second quarter 2018 was $5.4 million, or $0.17 per basic and diluted share, compared to a net loss of $1.5 million, or $0.15 per basic and diluted share, for the same period in 2017. The increase in net loss year-over-year is primarily attributable to an increase in research and development costs of $3.3 million associated with the clinical development of PRV-6527 and PRV-300, the development of PRV-101, and costs for PRV-031, which was acquired from MacroGenics in May 2018, as well as an increase in general and administrative costs of $0.8 million.
Net loss for the nine months ended 2018 was $21.1 million, or $1.21 per basic and diluted share, compared to a net loss of $5.7 million, or $0.62 per basic and diluted share, for the same period in 2017. The increase in net loss year-over-year is primarily attributable to an increase in research and development costs of $13.1 million associated with clinical development of PRV-6527 and PRV-300, the development expenses related to PRV-101, and costs related to the expansion of our clinical pipeline with two additional assets from MacroGenics in May 2018, as well as an increase in general and administrative costs of $2.1 million.
Conference Call Information:
Provention will host a conference call and live audio webcast on Thursday, November 8, 2018, at 8:30 a.m. ET, to discuss its corporate and financial results for the third quarter of 2018. Interested participants and investors may access the conference call by dialing either:
An audio webcast will be accessible via the Investors section of the Provention website http://investors.proventionbio.com/home. An archive of the webcast will remain available for 90 days beginning later today, November 8, 2018, at approximately 9:30 a.m. ET.
About Provention Bio, Inc.
Provention Bio, Inc. (Nasdaq: PRVB) is a clinical-stage biopharmaceutical company leveraging a transformational drug development strategy that is focused on the prevention or interception of immune-mediated disease. Provention's diverse portfolio was assembled with product candidates that have undergone clinical testing but may have been underdeveloped or deprioritized assets at other companies. Provention's mission is to in-license, transform and develop clinical-stage, or nearly clinical-stage, therapeutic candidates targeting the high morbidity, mortality and escalating costs of autoimmune and inflammatory diseases including: type 1 diabetes (T1D), Crohn's disease, ulcerative colitis, celiac disease, lupus, and certain life-threating viral diseases. For more information on Provention Bio, please visit www.proventionbio.com.
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," and "intend," among others. These forward-looking statements are based on Provention's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to failure to obtain FDA approvals or clearances and noncompliance with FDA regulations; uncertainties of patent protection and litigation; limited research and development efforts and dependence upon third parties; substantial competition; our need for additional financing and the risks listed under "Risk factors" in our quarterly report on Form 10-Q for the quarter ended June 30, 2018 and any subsequent filings with the Securities and Exchange Commission (SEC). As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Provention does not undertake an obligation to update or revise any forward-looking statement. The information set forth herein speaks only as of the date hereof.
Financial Tables to Follow
PROVENTION BIO, INC.
SELECTED FINANCIAL DATA (unaudited)
(in thousands, except per share data)
Three Months Ended September 30,
Nine Months Ended September 30,
Statement of Operations Data:
Research and development
General and administrative
Total operating expenses
Other income (expense):
Change in fair value of warrant liability
Accretion on Series A Convertible Redeemable Preferred Stock
Net loss attributable to common stockholders
Net loss per common share, basic and diluted
Weighted average common shares outstanding, basic and diluted
September 30, 2018
December 31, 2017
Balance Sheet Data:
Cash and cash equivalents
Series A Convertible Redeemable Preferred Stock
Total stockholders' equity (deficit)
SOURCE Provention Bio, Inc.